Pegfilgrastim Next As Fresenius Kabi Eyes Five Biosimilars In 2025
High Triple-Digit Million-Euro Sales Forecasted From 2024
Fresenius Kabi has drawn up a roadmap to offering five biosimilar products by 2025, with a biosimilar to Amgen’s Neulasta (pegfilgrastim) set to rival competitors in the US and Europe later this year, ahead of a biosimilar to Roche and Chugai’s Actemra/Ro-Actemra (tocilizumab).
